Clinical trial
A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer Who Had Failed Therapy With PD-1/L1 Inhibitor
NCT05431569 is registered in ClinicalTrials.gov with Mabwell (Shanghai) Bioscience Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer Who Had Failed Therapy With PD-1/L1 Inhibitor
- Lead sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 10, 2022
- Completion date
- September 10, 2023
- Enrollment
- 36 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
advanced lung cancer